Overview

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

Status:
Enrolling by invitation

Trial end date:
2023-04-01

Target enrollment:

Participant gender:

Summary

This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy

Phase:

Phase 3

Details

Lead Sponsor:

Zogenix, Inc.

Collaborator:

Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

Treatments:

Fenfluramine